Table 1. Characteristics of included studies.

Authors	Location	Study Period, median follow-up (y) after TC-PI	Number of patients with TC-PI	Proportion of patients with known small bowel disease at time of surgery (%)	Definition of clinical recurrence	5- and 10-year risk of clinical recurrence	5- and 10-year risk of surgical recurrence
Korelitz, 1972	New York, USA	1940-1970, NR	67	NR	NR	-	-
Steinberg, 1974	Birmingham, UK	1942-1973, 9y	73	52	New-onset symptoms	20%, NR	-
Weterman, 1976	Leuven, Belgium	1934-1972, 8.3y	16	NR	NR	-	-
Vender, 1979	Connecticut, USA	1958-1974, 8.8y	34	62	NR	27%, 40%	-
Goligher, 1985	Leeds, UK	1959-1984, 15y	162	NR	NR	NR, 60%	-
Ritchie, 1990	London, UK	1952-1988, NR	182	NR	NR	7%, 11%	-
Harling, 1991	Copenhagen, Denmark	1964-1989, 7.7y	84	0	NR	-	29%, NR
Heimann, 1993	New York, USA	1976-1989, 3y	37	NR	New-onset symptoms, confirmed by imaging or endoscopy	-	-
Ho, 1995	New York, USA	1952-1984, 6.8y	182	64	NR	-	NR, 34%
Yamamoto, 2000	Birmingham, UK	1958-1997, 18.6y	103	36	New-onset symptoms, confirmed by imaging,	-	13%, 17%
Ecker, 2001	Homburg, Germany	NR, 5.4y	92	NR	NR	-	3%, 14%
Bernell, 2001	Huddinge, Sweden	1955-1989, 12.9y	89	NR	New-onset symptoms, confirmed by imaging, endoscopy or need for re-initiation of IBD-related therapy	24%, 37%	-
Fichera, 2005	Illinois, USA	1985-2003, 1.2y	76	0	NR	-	9%, 20%
Onali, 2009	Rome, Italy	2001-2007	14	NR	New-onset symptoms, confirmed by imaging, endoscopy	-	-
Amiot, 2011	Paris, France	1990-2005	55	58	New-onset symptoms, confirmed by imaging, endoscopy or need for re-initiation of IBD-related therapy	27%, 40%	10%, NR
Koriche, 2012	Paris, France	1973-2010	83	54	New-onset symptoms, with need for re-initiation or escalation of IBD-related therapy	-	-
Leal-Valdivieso, 2012	Barcelona, Spain	-	16	37	NR	-	-
Lopez, 2014	Massachusetts, USA	NR, 1.6y	73	35	New-onset symptoms, confirmed by imaging, endoscopy or histology	35%, NR	-

Abbreviations: NR, not reported; y, years